Bernstein Cuts PT on Smith & Nephew plc (SNN)

Smith & Nephew plc (NYSE:SNN) is one of the best robotic surgery stocks to buy. Bernstein cut the price target on Smith & Nephew plc (NYSE:SNN) to $31.85 from $36.20 on May 11, maintaining a Market Perform rating on the shares. The rating update came after the company provided a fiscal Q1 trading update on May 6, with the firm noting that reported sales were up 3.1% organically, missing consensus growth of 3.8%.

RBC Capital Raises Price Target on Smith & Nephew (SNN) Ahead of Capital Markets Day

Smith & Nephew plc (NYSE:SNN) also received a rating update from Canaccord the same day, with the firm cutting the price target on the stock to $30 from $32 and maintaining a Hold rating on the shares. The firm updated its model on the stock after its fiscal Q1 results to take into account comp-group compression.

In its financial results for fiscal Q1 2026, Smith & Nephew plc (NYSE:SNN) reported revenue of $1,501 million, with underlying revenue growth of 3.1%, and reported revenue growth of 6.6%, which included a 350bps foreign exchange tailwind.

Smith & Nephew plc (NYSE:SNN) develops, manufactures, markets, and sells medical devices. Its operations are divided into the following segments: Orthopedics, Sports Medicine and ENT, and Advanced Wound Management.

While we acknowledge the risk and potential of SNN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than SNN and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1